Skip to content

CG Oncology CGON Change in Inventories

Change in Inventories at other companies

Pfizer logo
PfizerPFE
-$140.25M-166%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$431M+195%
Gilead Sciences logo
Gilead SciencesGILD
$52M-76.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$4.99M+2,798%
Exelixis logo
ExelixisEXEL
$3.39M+4,673%
Biogen logo
BiogenBIIB
-$116.2M-87.4%

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.8B+206%

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInInventories.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's change in inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's change in inventories?
CG Oncology (CGON) reported change in inventories of -$72K in Q1 2026.
What does change in inventories mean?
Increase or decrease in inventory levels, directly affecting operating cash flow and working capital.